Central sensitization as a predictive factor for the surgical outcome in patients with lumbar spinal stenosis: a multicenter prospective study.

Purpose: The impact of central sensitization (CS) on neurological symptoms and surgical outcomes in patients with lumbar spinal stenosis (LSS) remains unknown. This study aimed to investigate the influence of preoperative CS on the surgical outcomes of patients with LSS.

Methods: A total of 197 consecutive patients with LSS (mean age 69.

Evaluation of Central Sensitization Inventory in Patients Undergoing Elective Spine Surgery in a Multicenter Study.

Study Design: This study is a retrospective review.

Objective: Central sensitization (CS) is a neurological phenomenon that involves hypersensitivity of the central nervous system. The central sensitization inventory (CSI) was developed as a screening tool to assess CS-related symptoms.

Second rebound-associated vertebral fractures after denosumab discontinuation.

Here, we report the case of a 69-year-old female who discontinued denosumab to undergo dental treatment. She subsequently suffered rebound-associated vertebral fractures (RVFs) twice. Denosumab is approved in several countries for osteoporosis treatment.

Efficacy of Switching From Teriparatide to Bisphosphonate or Denosumab: A Prospective, Randomized, Open-Label Trial.

There is no consensus on an optimal treatment after daily teriparatide (TPTD). We performed a prospective, randomized, open-label, 12-month trial to investigate the efficacy of follow-up treatment after daily TPTD treatment for Japanese patients. Three-hundred patients were enrolled in this study.

Efficacy of Daily Teriparatide Treatment in Low Levels of Walking State Patients.

Introduction: Little is known about the efficacy of osteoporosis medication in patients with low levels of walking state, namely, influence by immobilization levels. We retrospectively compared the efficacy of the daily teriparatide therapy in patients with low and high levels of walking state to detect possible immobilization-related differences.

Methods: We analyzed 661 patients treated with 20 μg/day of teriparatide for 24 months.

The Relationship of BMD Increases Between the First 12 Months and the Latter 12 Months by Daily Teriparatide Treatment.

The degree of correlation between the first 12 months and the latter 12 months of increased bone mineral density (BMD) with teriparatide treatment is unknown. We retrospectively investigated the correlation between the first 12 months and the latter 12 months of increased BMD owing to teriparatide treatment. We retrospectively analyzed 357 patients (mean age, 78 years) with osteoporosis treated with teriparatide 20 μg/day for 24 months.

Cortical thickness of the femur and long-term bisphosphonate use.

Femoral cortical thickening has been mentioned in reports of atypical subtrochanteric/femoral shaft (ST/FS) fractures, which are associated with long-term bisphosphonate (BP) use. However, whether thickening precedes BP use or results from BP use, as well as the role BPs may play in cortical thickening remain unclear. The purpose of this study was to investigate the relationship between cortical thickness and BP use.

Determinants associated with bone mineral density increase in response to daily teriparatide treatment in patients with osteoporosis.

Introduction: Several factors associated with bone mineral density (BMD) increase are reported with daily teriparatide treatment, but there has been no systematic analysis to summarize these associations. The purpose of this study was to investigate the clinical determinants associated with BMD increase to daily teriparatide treatment.

Methods: This was a retrospective study.

Primary Ewing sarcoma of the spine mimicking a psoas abscess secondary to spinal infection.

Study Design: A case of primary Ewing sarcoma of the lumbar spine is presented.

Objective: To present and review a rare case of primary Ewing sarcoma of the lumbar spine that required differentiation from spinal infection.

Summary Of Background Data: Primary Ewing sarcoma originating from the spinal column is very rare.

Thoracic myelopathy with alkaptonuria.

Study Design: A case of thoracic myelopathy with alkaptonuria (ochronotic spondyloarthropathy) is presented.

Objective: To present and review the first reported case of an alkaptonuric patient with concomitant thoracic myelopathy.

Summary Of Background Data: Alkaptonuria, a rare hereditary metabolic disease, is characterized by accumulation of homogentistic acid, ochronosis, and destruction of connective tissue resulting in degenerative spondylosis and arthritis.